Articles related to CHEMOTHERAPY

Tafasitamab plus lenalidomide added to R-CHOP reduced the risk of progression or death by 25% compared with R-CHOP alone in previously untreated high-risk DLBCL and HGBL in a 899-patient phase 3 trial, with overall survival data not yet mature.

A phase 3 randomized trial of 449 children with intracranial ependymoma found no significant event-free or overall survival benefit from adding maintenance chemotherapy after radiation, while molecular markers — particularly 1q gain and 6q loss — identified a high-risk posterior fossa subgroup with substantially worse outcomes.

DAGO2 produced 3-year overall survival of 52% versus 35% with CPX-351 in older patients with non-adverse-risk AML in a 439-patient randomized comparison.

“The SunRISe-2 trial was stopped in advance for futility based on week-18 overall response rate assessment and the totality of the efficacy data. However, the CR rates in both arms are compelling.” — Andrea Necchi, MD, ASCO GU Symposium 2026

“Patients treated in the Optune Pax arm had a median time to pain progression of 15.2 months compared to 9.1 months.” — PANOVA-3 Trial, FDA Approval Announcement

“The damage to DNA lasts a lifetime. Probably the biggest concern is the increased risk of other cancers developing as a result of exposure to prior chemotherapy.”